Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab
| Title: | Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab |
|---|---|
| Authors: | Hasan Cagri Yildirim, Hicran Anik, Deniz Ates Ozdemir, Rashad Ismayilov, Arif Akyildiz, Kerim Cayiroz, Fahri Ceyhan, Oguzalp Kavruk, Deniz Can Guven, Ozturk Ates, Alp Usubutun, Zafer Arik |
| Source: | Biomolecules & Biomedicine (2024) |
| Publisher Information: | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Biology (General) |
| Subject Terms: | Metastatic cervical cancer, squamous cell carcinoma (SCC), vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1 alpha (HIF-1 alpha), bevacizumab, Biology (General), QH301-705.5 |
| More Details: | This study addresses the gap in understanding the prognostic relevance of hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression in metastatic cervical squamous cell carcinoma (SCC) patients undergoing anti-vascular endothelial growth factor-based therapy. A retrospective multicenter study (n = 34) explored HIF-1 alpha expression via immunohistochemistry in patients treated with platinum chemotherapy and bevacizumab. Median progression-free survival (PFS) was significantly lower in the HIF-1 alpha low score group compared to the high score group (4.9 vs 12.9 months, P = 0.014). Similarly, the median overall survival (OS) was significantly reduced in the HIF-1 alpha low score group (8.3 vs 20.4 months, P = 0.006). This study, the first of its kind, highlights the prognostic significance of HIF-1 alpha expression in metastatic cervical SCC patients treated with bevacizumab-based therapy. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2831-0896 2831-090X |
| Relation: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/10255; https://doaj.org/toc/2831-0896; https://doaj.org/toc/2831-090X |
| DOI: | 10.17305/bb.2024.10255 |
| Access URL: | https://doaj.org/article/0a6679b01dca4c8a82ddcef55b98579d |
| Accession Number: | edsdoj.0a6679b01dca4c8a82ddcef55b98579d |
| Database: | Directory of Open Access Journals |
| ISSN: | 28310896 2831090X |
|---|---|
| DOI: | 10.17305/bb.2024.10255 |
| Published in: | Biomolecules & Biomedicine |
| Language: | English |